|
시장보고서
상품코드
2132511
환각제 시장 규모, 점유율, 동향 분석 보고서 : 약제 종류별, 적응증별, 투여 경로별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)Psychedelic Drugs Market Size, Share & Trends Analysis Report By Drug Type (Entactogens, Dissociatives), By Indication, By Route of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
환각제 시장 요약
세계의 환각제 시장 규모는 2025년에 41억 달러로 평가되며, 2026년 47억 달러에서 2033년까지 117억 달러로 확대될 것으로 예상되며, 2026년부터 2033년까지 CAGR은 14.1%에 달할 것으로 예측됩니다.
북미가 시장을 주도하고 있으며, 2025년에는 매출 점유율의 41.2%를 차지했습니다. 이 시장은 정신 질환 및 물질 사용 장애 치료를 목적으로 한 환각성 화합물 개발에 초점을 맞춘 신흥 의약품 시장입니다.
임상시험 대상인 주요 물질로는 실로시빈, 3,4-메틸렌디옥시메탐페타민(MDMA), N,N-디메틸트립타민(DMT), 이보가인 등이 있습니다. 이 조사는 주로 치료 저항성 우울증, 주요 우울 장애, 외상 후 스트레스 장애(PTSD), 그리고 알코올사용장애에 초점을 맞추고 있습니다. 이 시장은 진행 중인 임상시험, 생명공학 기업 및 제약 기업의 투자, 그리고 기존 치료법에 충분한 반응을 보이지 않는 환자를 위한 치료법 연구에 의해 뒷받침되고 있습니다. 그러나 대부분의 환각제는 여전히 임상 개발 단계에 있기 때문에 현재 시판 상황은 제한적입니다. 또한 개발 과정에는 규제 약물에 대한 규정, 전문적인 투여 프로토콜, 환자 모니터링, 그리고 심리적 지원이 수반됩니다. 이러한 요건들은 개발 비용과 치료비를 증가시킬 가능성이 있어, 환각제를 기반으로 한 치료법의 보급에 영향을 미칠 우려가 있습니다. 장기적인 안전성 데이터의 부족, 규제 측면의 불확실성, 그리고 훈련된 의료 인력의 필요성은 여전히 시장 발전에 영향을 미치는 주요 요인으로 남아 있습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 환각제 시장 : 변수, 동향, 범위
제4장 환각제 시장 : 약물 유형별 비즈니스 분석
제5장 환각제 시장 : 적응증별 비즈니스 분석
제6장 환각제 시장 : 투여 경로별 비즈니스 분석
제7장 환각제 시장 : 유통 채널별 비즈니스 분석
제8장 환각제 시장 : 지역별 추정·동향 분석
제9장 경쟁 구도
KSM 26.09.28Psychedelic Drugs Market Summary
The global psychedelic drugs market size was valued at USD 4.1 billion in 2025 and is projected to grow from USD 4.7 billion in 2026 to USD 11.7 billion by 2033, at a CAGR of 14.1% from 2026 to 2033. North America dominated the market, accounting for revenue share of 41.2% in 2025. The market is an emerging pharmaceutical market focused on the development of psychedelic compounds for the treatment of mental health and substance use disorders.
Key substances under clinical investigation include psilocybin, 3,4-methylenedioxymethamphetamine (MDMA), N,N-dimethyltryptamine (DMT), and ibogaine. Research is primarily focused on treatment-resistant depression, major depressive disorder, post-traumatic stress disorder, and alcohol use disorder. The market is supported by ongoing clinical trials, investments by biotechnology and pharmaceutical companies, and research into treatment options for patients with inadequate response to existing therapies. However, most psychedelic drugs remain in clinical development, limiting their current commercial availability. Development also involves controlled-substance regulations, specialized administration protocols, patient monitoring, and psychological support. These requirements can increase development and treatment costs and may affect the adoption of psychedelic-based therapies. Limited long-term safety data, regulatory uncertainty, and the need for trained healthcare professionals remain key factors affecting market development.
Global Psychedelic Drugs Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global psychedelic drugs market report based on drug type, indication, route of administration, distribution channel, and region:
- Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
- Classical Psychedelics
- Entactogens
- Dissociatives
- Others
- Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Depressive Disorders
- Trauma- and Stressor-Related Disorders
- Anxiety Disorders
- Substance Use Disorders
- Obsessive-Compulsive and Related Disorders
- End-of-Life Psychological Distress
- Others
- Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
- Oral
- Intranasal
- Parenteral
- Others
- Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Hospital Pharmacies
- Specialty Pharmacies
- Retail Pharmacies
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Drug Type
- 1.2.2. Indication
- 1.2.3. Route of Administration
- 1.2.4. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Psychedelic Drugs Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Psychedelic Drugs Market: Drug Type Business Analysis
- 4.1. Drug Type Market Share, 2025 & 2033
- 4.2. Drug Type Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
- 4.4. Classical Psychedelics
- 4.4.1. Classical Psychedelics Market, 2021 - 2033 (USD Million)
- 4.5. Entactogens
- 4.5.1. Entactogens Market, 2021 - 2033 (USD Million)
- 4.6. Dissociatives
- 4.6.1. Dissociatives Market, 2021 - 2033 (USD Million)
- 4.7. Others
- 4.7.1. Others Market, 2021 - 2033 (USD Million)
Chapter 5. Psychedelic Drugs Market: Indication Business Analysis
- 5.1. Indication Market Share, 2025 & 2033
- 5.2. Indication Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
- 5.4. Depressive Disorders
- 5.4.1. Depressive Disorders Market, 2021 - 2033 (USD Million)
- 5.5. Trauma- and Stressor-Related Disorders
- 5.5.1. Trauma- and Stressor-Related Disorders Market, 2021 - 2033 (USD Million)
- 5.6. Anxiety Disorders
- 5.6.1. Anxiety Disorders Market, 2021 - 2033 (USD Million)
- 5.7. Substance Use Disorders
- 5.7.1. Substance Use Disorders Market, 2021 - 2033 (USD Million)
- 5.8. Obsessive-Compulsive and Related Disorders
- 5.8.1. Obsessive-Compulsive and Related Disorders Market, 2021 - 2033 (USD Million)
- 5.9. End-of-Life Psychological Distress
- 5.9.1. End-of-Life Psychological Distress Market, 2021 - 2033 (USD Million)
- 5.10. Others
- 5.10.1. Others Market, 2021 - 2033 (USD Million)
Chapter 6. Psychedelic Drugs Market: Route of Administration Business Analysis
- 6.1. Route of Administration Market Share, 2025 & 2033
- 6.2. Route of Administration Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
- 6.4. Oral
- 6.4.1. Oral Market, 2021 - 2033 (USD Million)
- 6.5. Intranasal
- 6.5.1. Intranasal Market, 2021 - 2033 (USD Million)
- 6.6. Parenteral
- 6.6.1. Parenteral Market, 2021 - 2033 (USD Million)
- 6.7. Others
- 6.7.1. Others Market, 2021 - 2033 (USD Million)
Chapter 7. Psychedelic Drugs Market: Distribution Channel Business Analysis
- 7.1. Distribution Channel Market Share, 2025 & 2033
- 7.2. Distribution Channel Segment Dashboard
- 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
- 7.4. Hospital Pharmacies
- 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
- 7.5. Specialty Pharmacies
- 7.5.1. Specialty Pharmacies Market, 2021 - 2033 (USD Million)
- 7.6. Retail Pharmacies
- 7.6.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
- 7.7. Others
- 7.7.1. Others Market, 2021 - 2033 (USD Million)
Chapter 8. Psychedelic Drugs Market: Regional Estimates & Trend Analysis
- 8.1. Regional Market Share Analysis, 2025 & 2033
- 8.2. Regional Market Dashboard
- 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 8.4. North America
- 8.4.1. North America Psychedelic Drugs Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 8.4.2. U.S.
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Target Disease Prevalence
- 8.4.2.3. Regulatory Framework
- 8.4.2.4. Reimbursement Framework
- 8.4.2.5. U.S.Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.3. Canada
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Target Disease Prevalence
- 8.4.3.3. Regulatory Framework
- 8.4.3.4. Reimbursement Framework
- 8.4.3.5. Canada Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.4. Mexico
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Target Disease Prevalence
- 8.4.4.3. Regulatory Framework
- 8.4.4.4. Reimbursement Framework
- 8.4.4.5. Mexico Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5. Europe
- 8.5.1. Europe Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.2. UK
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Target Disease Prevalence
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Reimbursement Framework
- 8.5.2.5. UK Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.3. Germany
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Target Disease Prevalence
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. Reimbursement Framework
- 8.5.3.5. Germany Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.4. France
- 8.5.4.1. Key Country Dynamics
- 8.5.4.2. Target Disease Prevalence
- 8.5.4.3. Regulatory Framework
- 8.5.4.4. Reimbursement Framework
- 8.5.4.5. France Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.5. Italy
- 8.5.5.1. Key Country Dynamics
- 8.5.5.2. Target Disease Prevalence
- 8.5.5.3. Regulatory Framework
- 8.5.5.4. Reimbursement Framework
- 8.5.5.5. Italy Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.6. Spain
- 8.5.6.1. Key Country Dynamics
- 8.5.6.2. Target Disease Prevalence
- 8.5.6.3. Regulatory Framework
- 8.5.6.4. Reimbursement Framework
- 8.5.6.5. Spain Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.7. Denmark
- 8.5.7.1. Key Country Dynamics
- 8.5.7.2. Target Disease Prevalence
- 8.5.7.3. Regulatory Framework
- 8.5.7.4. Reimbursement Framework
- 8.5.7.5. Denmark Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.8. Sweden
- 8.5.8.1. Key Country Dynamics
- 8.5.8.2. Target Disease Prevalence
- 8.5.8.3. Regulatory Framework
- 8.5.8.4. Reimbursement Framework
- 8.5.8.5. Sweden Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.9. Norway
- 8.5.9.1. Key Country Dynamics
- 8.5.9.2. Target Disease Prevalence
- 8.5.9.3. Regulatory Framework
- 8.5.9.4. Reimbursement Framework
- 8.5.9.5. Norway Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6. Asia Pacific
- 8.6.1. Asia Pacific Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.2. Japan
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Target Disease Prevalence
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. Reimbursement Framework
- 8.6.2.5. Japan Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.3. China
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Target Disease Prevalence
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. Reimbursement Framework
- 8.6.3.5. China Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.4. India
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Target Disease Prevalence
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. Reimbursement Framework
- 8.6.4.5. India Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.5. Australia
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Target Disease Prevalence
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Reimbursement Framework
- 8.6.5.5. Australia Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.6. South Korea
- 8.6.6.1. Key Country Dynamics
- 8.6.6.2. Target Disease Prevalence
- 8.6.6.3. Regulatory Framework
- 8.6.6.4. Reimbursement Framework
- 8.6.6.5. South Korea Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.7. Thailand
- 8.6.7.1. Key Country Dynamics
- 8.6.7.2. Target Disease Prevalence
- 8.6.7.3. Regulatory Framework
- 8.6.7.4. Reimbursement Framework
- 8.6.7.5. Thailand Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7. Latin America
- 8.7.1. Latin America Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.2. Brazil
- 8.7.2.1. Key Country Dynamics
- 8.7.2.2. Target Disease Prevalence
- 8.7.2.3. Regulatory Framework
- 8.7.2.4. Reimbursement Framework
- 8.7.2.5. Brazil Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.3. Argentina
- 8.7.3.1. Key Country Dynamics
- 8.7.3.2. Target Disease Prevalence
- 8.7.3.3. Regulatory Framework
- 8.7.3.4. Reimbursement Framework
- 8.7.3.5. Argentina Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8. Middle East and Africa
- 8.8.1. Middle East and Africa Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.2. South Africa
- 8.8.2.1. Key Country Dynamics
- 8.8.2.2. Target Disease Prevalence
- 8.8.2.3. Regulatory Framework
- 8.8.2.4. Reimbursement Framework
- 8.8.2.5. South Africa Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.3. Saudi Arabia
- 8.8.3.1. Key Country Dynamics
- 8.8.3.2. Target Disease Prevalence
- 8.8.3.3. Regulatory Framework
- 8.8.3.4. Reimbursement Framework
- 8.8.3.5. Saudi Arabia Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.4. UAE
- 8.8.4.1. Key Country Dynamics
- 8.8.4.2. Target Disease Prevalence
- 8.8.4.3. Regulatory Framework
- 8.8.4.4. Reimbursement Framework
- 8.8.4.5. UAE Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.5. Kuwait
- 8.8.5.1. Key Country Dynamics
- 8.8.5.2. Target Disease Prevalence
- 8.8.5.3. Regulatory Framework
- 8.8.5.4. Reimbursement Framework
- 8.8.5.5. Kuwait Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Participant Overview
- 9.2. Company Market Position Analysis
- 9.3. Company Categorization
- 9.4. Strategy Mapping
- 9.5. Company Profiles/Listing
- 9.5.1. Compass Pathways plc.
- 9.5.1.1. Overview
- 9.5.1.2. Financial Performance
- 9.5.1.3. Product Benchmarking
- 9.5.1.4. Strategic Initiatives
- 9.5.2. Definium Therapeutics, Inc.
- 9.5.2.1. Overview
- 9.5.2.2. Financial Performance
- 9.5.2.3. Product Benchmarking
- 9.5.2.4. Strategic Initiatives
- 9.5.3. Helus Pharma Inc.
- 9.5.3.1. Overview
- 9.5.3.2. Financial Performance
- 9.5.3.3. Product Benchmarking
- 9.5.3.4. Strategic Initiatives
- 9.5.4. GH Research plc.
- 9.5.4.1. Overview
- 9.5.4.2. Financial Performance
- 9.5.4.3. Product Benchmarking
- 9.5.4.4. Strategic Initiatives
- 9.5.5. Johnson & Johnson
- 9.5.5.1. Overview
- 9.5.5.2. Financial Performance
- 9.5.5.3. Product Benchmarking
- 9.5.5.4. Strategic Initiatives
- 9.5.6. Eli Lilly and Company
- 9.5.6.1. Overview
- 9.5.6.2. Financial Performance
- 9.5.6.3. Product Benchmarking
- 9.5.6.4. Strategic Initiatives
- 9.5.7. Otsuka Pharmaceutical Co., Ltd.
- 9.5.7.1. Overview
- 9.5.7.2. Financial Performance
- 9.5.7.3. Product Benchmarking
- 9.5.7.4. Strategic Initiatives
- 9.5.8. AbbVie Inc.
- 9.5.8.1. Overview
- 9.5.8.2. Financial Performance
- 9.5.8.3. Product Benchmarking
- 9.5.8.4. Strategic Initiatives
- 9.5.9. Incannex Healthcare Limited
- 9.5.9.1. Overview
- 9.5.9.2. Financial Performance
- 9.5.9.3. Product Benchmarking
- 9.5.9.4. Strategic Initiatives
- 9.5.10. Optimi Health Corp.
- 9.5.10.1. Overview
- 9.5.10.2. Financial Performance
- 9.5.10.3. Product Benchmarking
- 9.5.10.4. Strategic Initiatives
- 9.5.1. Compass Pathways plc.
